论文部分内容阅读
目的：研究表皮生长因子受体（ＥＧＦＲ）在乳腺癌原发灶及转移淋巴结中的表达，以探讨ＥＧＦＲ对乳腺癌预后的影响。方法：采用免疫组化Ｓ－Ｐ法以抗ＥＧＦＲＰｃＡｂ对４２例乳腺癌原发灶及转移淋巴结进行标记。结果：４２例乳腺癌标本中，１９例病理Ⅲ级的ＥＧＦＲ表达阳性率为７３．７％，明显高于２３例病理Ⅰ～Ⅱ级的３９．１％；有腋窝淋巴结转移的２６例ＥＧＦＲ阳性率为６９．２％，高于无转移的１６例（３１．３％）；雌激素受体阳性（ＥＲ＋）的２４例ＥＧＦＲ阳性率明显低于ＥＲ－的１８例（３７．５％与７７．８％）；在转移淋巴结中ＥＧＦＲ阳性率高于原发灶（９２．３％与６９．２％）。通过χ２检验，Ｐ值均小于０．０５。结论：乳腺癌ＥＧＦＲ过度表达可做为乳腺癌内分泌治疗及估计预后的一项客观指标。
Objective: To investigate the expression of epidermal growth factor receptor (EGFR) in primary breast cancer and metastatic lymph nodes in order to explore the effect of EGFR on the prognosis of breast cancer. Methods: Using immunohistochemical S-P method, 42 primary breast cancer lesions and metastatic lymph nodes were labeled with anti-EGFRPcAb. RESULTS: Of the 42 breast cancer specimens, the positive rate of EGFR expression in 19 cases of grade III EGFR was 73.7%, which was significantly higher than that of 39 cases of pathological grade I-II; 26 cases of axillary lymph node metastases were positive for EGFR. The rate was 69.2%, higher than 16 cases without metastasis (31.3%); the positive rate of EGFR in 24 cases of estrogen receptor positive (ER+) was significantly lower than that of ER-(18 cases, 37.5% and 77%). .8%); The positive rate of EGFR was higher in the metastatic lymph nodes than in the primary tumors (92.3% and 69.2%). Through the χ2 test, P values were all less than 0.05. Conclusion: The over-expression of EGFR in breast cancer can be used as an objective indicator of endocrine therapy and the prognosis of breast cancer.